Annual CFO
-$500.99 M
-$175.65 M-53.99%
31 December 2023
Summary:
Sarepta Therapeutics annual cash flow from operations is currently -$500.99 million, with the most recent change of -$175.65 million (-53.99%) on 31 December 2023. During the last 3 years, it has fallen by -$57.82 million (-13.05%). SRPT annual CFO is now -566.19% below its all-time high of $107.47 million, reached on 31 December 2020.SRPT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$70.70 M
-$85.64 M-573.16%
30 September 2024
Summary:
Sarepta Therapeutics quarterly cash flow from operations is currently -$70.70 million, with the most recent change of -$85.64 million (-573.16%) on 30 September 2024. Over the past year, it has dropped by -$16.04 million (-29.35%). SRPT quarterly CFO is now -111.26% below its all-time high of $627.79 million, reached on 31 March 2020.SRPT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$352.49 M
+$44.01 M+11.10%
30 September 2024
Summary:
Sarepta Therapeutics TTM cash flow from operations is currently -$352.49 million, with the most recent change of +$44.01 million (+11.10%) on 30 September 2024. Over the past year, it has increased by +$148.50 million (+29.64%). SRPT TTM CFO is now -211.00% below its all-time high of $317.56 million, reached on 31 March 2020.SRPT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -29.4% | +29.6% |
| 3 y3 years | -13.1% | -141.1% | +20.5% |
| 5 y5 years | -9.8% | +56.8% | +22.8% |
SRPT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -54.0% | at low | -573.2% | +70.8% | -34.4% | +34.6% |
| 5 y | 5 years | -566.2% | at low | -111.3% | +70.8% | -211.0% | +49.8% |
| alltime | all time | -566.2% | at low | -111.3% | +70.8% | -211.0% | +49.8% |
Sarepta Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$70.70 M(-573.2%) | -$352.49 M(-11.1%) |
| June 2024 | - | $14.94 M(-106.2%) | -$396.50 M(-25.7%) |
| Mar 2024 | - | -$242.08 M(+342.9%) | -$533.67 M(+6.5%) |
| Dec 2023 | -$500.99 M(+54.0%) | -$54.66 M(-52.4%) | -$500.99 M(-7.0%) |
| Sept 2023 | - | -$114.71 M(-6.2%) | -$538.73 M(+10.2%) |
| June 2023 | - | -$122.23 M(-41.6%) | -$488.99 M(+12.8%) |
| Mar 2023 | - | -$209.40 M(+126.6%) | -$433.57 M(+33.3%) |
| Dec 2022 | -$325.35 M(-26.6%) | -$92.39 M(+42.2%) | -$325.35 M(+24.0%) |
| Sept 2022 | - | -$64.96 M(-2.8%) | -$262.28 M(-18.5%) |
| June 2022 | - | -$66.81 M(-34.0%) | -$321.64 M(-11.6%) |
| Mar 2022 | - | -$101.17 M(+245.0%) | -$363.98 M(-17.9%) |
| Dec 2021 | -$443.17 M(-512.4%) | -$29.33 M(-76.4%) | -$443.17 M(-24.7%) |
| Sept 2021 | - | -$124.33 M(+13.9%) | -$588.38 M(-16.2%) |
| June 2021 | - | -$109.15 M(-39.5%) | -$702.24 M(+0.2%) |
| Mar 2021 | - | -$180.37 M(+3.3%) | -$700.70 M(-752.0%) |
| Dec 2020 | $107.47 M(-123.5%) | -$174.53 M(-26.7%) | $107.47 M(-9.1%) |
| Sept 2020 | - | -$238.19 M(+121.4%) | $118.21 M(-59.1%) |
| June 2020 | - | -$107.60 M(-117.1%) | $288.96 M(-9.0%) |
| Mar 2020 | - | $627.79 M(-483.3%) | $317.56 M(-169.6%) |
| Dec 2019 | -$456.46 M(+17.4%) | -$163.79 M(+142.9%) | -$456.46 M(+10.0%) |
| Sept 2019 | - | -$67.43 M(-14.6%) | -$415.09 M(-10.0%) |
| June 2019 | - | -$79.00 M(-46.0%) | -$460.98 M(-7.7%) |
| Mar 2019 | - | -$146.23 M(+19.5%) | -$499.23 M(+28.4%) |
| Dec 2018 | -$388.66 M(+67.5%) | -$122.42 M(+8.0%) | -$388.66 M(+30.7%) |
| Sept 2018 | - | -$113.32 M(-3.4%) | -$297.30 M(+22.9%) |
| June 2018 | - | -$117.25 M(+228.7%) | -$241.88 M(+15.3%) |
| Mar 2018 | - | -$35.67 M(+14.8%) | -$209.78 M(-9.6%) |
| Dec 2017 | -$232.00 M(-5.6%) | -$31.06 M(-46.4%) | -$232.00 M(-17.8%) |
| Sept 2017 | - | -$57.90 M(-32.0%) | -$282.17 M(-1.0%) |
| June 2017 | - | -$85.15 M(+47.1%) | -$284.88 M(+17.2%) |
| Mar 2017 | - | -$57.89 M(-28.7%) | -$243.02 M(-1.1%) |
| Dec 2016 | -$245.82 M(+64.5%) | -$81.23 M(+34.0%) | -$245.82 M(+25.5%) |
| Sept 2016 | - | -$60.62 M(+40.0%) | -$195.86 M(+7.9%) |
| June 2016 | - | -$43.28 M(-28.7%) | -$181.56 M(+8.8%) |
| Mar 2016 | - | -$60.69 M(+94.1%) | -$166.81 M(+11.6%) |
| Dec 2015 | -$149.47 M(+16.3%) | -$31.27 M(-32.5%) | -$149.47 M(+4.1%) |
| Sept 2015 | - | -$46.31 M(+62.3%) | -$143.64 M(+8.3%) |
| June 2015 | - | -$28.53 M(-34.2%) | -$132.65 M(-7.6%) |
| Mar 2015 | - | -$43.35 M(+70.3%) | -$143.62 M(+11.7%) |
| Dec 2014 | -$128.54 M(+98.7%) | -$25.45 M(-27.9%) | -$128.54 M(+6.3%) |
| Sept 2014 | - | -$35.32 M(-10.6%) | -$120.91 M(+14.6%) |
| June 2014 | - | -$39.50 M(+39.8%) | -$105.47 M(+35.3%) |
| Mar 2014 | - | -$28.27 M(+58.6%) | -$77.97 M(+20.5%) |
| Dec 2013 | -$64.69 M(+117.9%) | -$17.82 M(-10.3%) | -$64.69 M(+19.7%) |
| Sept 2013 | - | -$19.88 M(+65.6%) | -$54.03 M(+28.8%) |
| June 2013 | - | -$12.00 M(-19.9%) | -$41.96 M(+17.7%) |
| Mar 2013 | - | -$14.99 M(+109.5%) | -$35.64 M(+20.0%) |
| Dec 2012 | -$29.69 M(+25.4%) | -$7.16 M(-8.3%) | -$29.69 M(+5.4%) |
| Sept 2012 | - | -$7.80 M(+37.4%) | -$28.18 M(+1.0%) |
| June 2012 | - | -$5.68 M(-37.2%) | -$27.90 M(+23.1%) |
| Mar 2012 | - | -$9.05 M(+60.2%) | -$22.66 M(-4.3%) |
| Dec 2011 | -$23.68 M(+55.7%) | -$5.65 M(-24.9%) | -$23.68 M(+18.9%) |
| Sept 2011 | - | -$7.52 M(+1602.0%) | -$19.92 M(+31.3%) |
| June 2011 | - | -$442.00 K(-95.6%) | -$15.17 M(-20.0%) |
| Mar 2011 | - | -$10.07 M(+433.2%) | -$18.96 M(+24.7%) |
| Dec 2010 | -$15.21 M | -$1.89 M(-31.9%) | -$15.21 M(+5.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$2.77 M(-34.5%) | -$14.38 M(+7.8%) |
| June 2010 | - | -$4.24 M(-32.9%) | -$13.34 M(-1.1%) |
| Mar 2010 | - | -$6.31 M(+497.2%) | -$13.50 M(+53.4%) |
| Dec 2009 | -$8.80 M(-28.7%) | -$1.06 M(-39.2%) | -$8.80 M(-13.9%) |
| Sept 2009 | - | -$1.74 M(-60.4%) | -$10.22 M(-19.6%) |
| June 2009 | - | -$4.39 M(+171.8%) | -$12.71 M(+33.4%) |
| Mar 2009 | - | -$1.61 M(-34.8%) | -$9.53 M(-22.8%) |
| Dec 2008 | -$12.34 M(-50.0%) | -$2.48 M(-41.4%) | -$12.34 M(-28.2%) |
| Sept 2008 | - | -$4.23 M(+249.1%) | -$17.19 M(-2.2%) |
| June 2008 | - | -$1.21 M(-72.6%) | -$17.58 M(-25.5%) |
| Mar 2008 | - | -$4.43 M(-39.6%) | -$23.61 M(-4.3%) |
| Dec 2007 | -$24.68 M(+19.7%) | -$7.33 M(+58.6%) | -$24.68 M(+9.7%) |
| Sept 2007 | - | -$4.62 M(-36.2%) | -$22.49 M(-4.1%) |
| June 2007 | - | -$7.24 M(+31.7%) | -$23.45 M(+12.6%) |
| Mar 2007 | - | -$5.49 M(+6.8%) | -$20.82 M(+1.0%) |
| Dec 2006 | -$20.61 M(+40.5%) | -$5.15 M(-7.6%) | -$20.61 M(+1.9%) |
| Sept 2006 | - | -$5.57 M(+20.9%) | -$20.24 M(+30.6%) |
| June 2006 | - | -$4.61 M(-12.8%) | -$15.50 M(-0.5%) |
| Mar 2006 | - | -$5.29 M(+10.9%) | -$15.58 M(+6.2%) |
| Dec 2005 | -$14.67 M(-38.3%) | -$4.77 M(+475.4%) | -$14.67 M(+10.0%) |
| Sept 2005 | - | -$828.90 K(-82.3%) | -$13.33 M(-26.5%) |
| June 2005 | - | -$4.69 M(+7.1%) | -$18.15 M(-11.2%) |
| Mar 2005 | - | -$4.38 M(+27.6%) | -$20.43 M(-14.1%) |
| Dec 2004 | -$23.78 M(+36.0%) | -$3.43 M(-39.2%) | -$23.78 M(-4.8%) |
| Sept 2004 | - | -$5.65 M(-19.0%) | -$24.98 M(+9.6%) |
| June 2004 | - | -$6.97 M(-9.8%) | -$22.79 M(+20.8%) |
| Mar 2004 | - | -$7.73 M(+67.0%) | -$18.86 M(+7.9%) |
| Dec 2003 | -$17.48 M(-13.7%) | -$4.63 M(+33.8%) | -$17.48 M(+6.1%) |
| Sept 2003 | - | -$3.46 M(+13.6%) | -$16.47 M(-2.8%) |
| June 2003 | - | -$3.04 M(-52.0%) | -$16.94 M(-23.5%) |
| Mar 2003 | - | -$6.35 M(+75.4%) | -$22.14 M(+9.3%) |
| Dec 2002 | -$20.26 M(+58.0%) | -$3.62 M(-7.8%) | -$20.26 M(-0.2%) |
| Sept 2002 | - | -$3.93 M(-52.3%) | -$20.31 M(+5.3%) |
| June 2002 | - | -$8.24 M(+84.2%) | -$19.28 M(+32.9%) |
| Mar 2002 | - | -$4.47 M(+22.1%) | -$14.51 M(+13.1%) |
| Dec 2001 | -$12.82 M(+40.5%) | -$3.66 M(+26.1%) | -$12.82 M(+2.8%) |
| Sept 2001 | - | -$2.91 M(-16.1%) | -$12.48 M(+10.7%) |
| June 2001 | - | -$3.46 M(+24.1%) | -$11.27 M(+7.3%) |
| Mar 2001 | - | -$2.79 M(-15.9%) | -$10.50 M(+15.0%) |
| Dec 2000 | -$9.13 M(+20.1%) | -$3.32 M(+95.2%) | -$9.13 M(+18.4%) |
| Sept 2000 | - | -$1.70 M(-36.9%) | -$7.71 M(-2.5%) |
| June 2000 | - | -$2.69 M(+90.1%) | -$7.91 M(+6.7%) |
| Mar 2000 | - | -$1.42 M(-25.4%) | -$7.42 M(-2.4%) |
| Dec 1999 | -$7.60 M(+13.4%) | -$1.90 M(0.0%) | -$7.60 M(-3.8%) |
| Sept 1999 | - | -$1.90 M(-13.6%) | -$7.90 M(+25.4%) |
| June 1999 | - | -$2.20 M(+37.5%) | -$6.30 M(-1.6%) |
| Mar 1999 | - | -$1.60 M(-27.3%) | -$6.40 M(-4.5%) |
| Dec 1998 | -$6.70 M(+123.3%) | -$2.20 M(+633.3%) | -$6.70 M(+19.6%) |
| Sept 1998 | - | -$300.00 K(-87.0%) | -$5.60 M(-11.1%) |
| June 1998 | - | -$2.30 M(+21.1%) | -$6.30 M(+40.0%) |
| Mar 1998 | - | -$1.90 M(+72.7%) | -$4.50 M(+50.0%) |
| Dec 1997 | -$3.00 M(+87.5%) | -$1.10 M(+10.0%) | -$3.00 M(+57.9%) |
| Sept 1997 | - | -$1.00 M(+100.0%) | -$1.90 M(+111.1%) |
| June 1997 | - | -$500.00 K(+25.0%) | -$900.00 K(+125.0%) |
| Mar 1997 | - | -$400.00 K | -$400.00 K |
| Dec 1996 | -$1.60 M | - | - |
FAQ
- What is Sarepta Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly CFO year-on-year change?
- What is Sarepta Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM CFO year-on-year change?
What is Sarepta Therapeutics annual cash flow from operations?
The current annual CFO of SRPT is -$500.99 M
What is the all time high annual CFO for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual cash flow from operations is $107.47 M
What is Sarepta Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SRPT is -$70.70 M
What is the all time high quarterly CFO for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly cash flow from operations is $627.79 M
What is Sarepta Therapeutics quarterly CFO year-on-year change?
Over the past year, SRPT quarterly cash flow from operations has changed by -$16.04 M (-29.35%)
What is Sarepta Therapeutics TTM cash flow from operations?
The current TTM CFO of SRPT is -$352.49 M
What is the all time high TTM CFO for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM cash flow from operations is $317.56 M
What is Sarepta Therapeutics TTM CFO year-on-year change?
Over the past year, SRPT TTM cash flow from operations has changed by +$148.50 M (+29.64%)